LegalAug 12, 2026, 07:38 AM
Arbutus Biopharma Reports $178.4M Moderna Settlement Payment
AI Summary
Arbutus Biopharma reported a significant financial turnaround, driven by a $178.4 million noncontingent payment received on July 8, 2026, as part of a settlement agreement with Moderna to resolve patent infringement litigation. The company also stands to receive an additional $1.3 billion contingent payment from Moderna upon a favorable appeal ruling. For the six months ended June 30, 2026, Arbutus recorded a net income of $164.552 million, a substantial improvement from a net loss in the prior year, with total revenue reaching $180.140 million. The company continues to pursue patent infringement lawsuits against Pfizer/BioNTech.
Key Highlights
- Received $178.4 million from Moderna settlement on July 8, 2026.
- Potential $1.3 billion contingent payment from Moderna upon favorable appeal ruling.
- Reported net income of $164.552 million for six months ended June 30, 2026.
- Total revenue reached $180.140 million for six months ended June 30, 2026.
- Basic earnings per share was $0.84 for six months ended June 30, 2026.
- Cash, cash equivalents, and marketable securities totaled $92.6 million as of June 30, 2026.
- Total current assets increased to $273.883 million as of June 30, 2026.
- Ongoing patent infringement lawsuits against Pfizer/BioNTech for LNP technology.
Price Impact
More from ABUS